HQL News and Press, TeklaLife Sciences Investors From 03/05/23

2023-03-05 07:56:14 ET Summary The HQH fund aims to provide high total returns through investments in the healthcare industry. HQH has a high allocation to risky biotech stocks and private investments. The fund pays a 2% of NAV quarterly distribution. However, HQH has under-earned...

Tekla Life Sciences ( NYSE: HQL ) declares $0.33/share quarterly dividend , 6.5% increase from prior dividend of $0.31. Forward yield 9.1% Payable March 31; for shareholders of record Feb. 27; ex-div Feb. 24. See HQL Dividend Scorecard, Yield Chart, & Dividen...

Summary PIMCO's Corporate & Income Opportunity Fund is hot. We share comparative data on over 100 big-yield CEFs, including performance, yield, strategy, discount versus premium, z-scores and more. We review four big-yield CEFs from the list (two that may be overheating and two ...

In the same way that the biopharma sector led the overall market lower in early 2022, biotech is already emerging as one of the sectors that is likely to lead the market higher as 2023 gets underway, suggests Nate Pile, editor of Nate's Notes. For further details see: Top Picks 2023- Tekla ...

Summary 2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve that doesn't want to let up on strangling inflation into submission while draini...

Summary We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds ("CEFs") and bonds. We dive deeper into three specific attractive big-yield opportunities that also have healthy upside potential. We begin with a special focus on...

Summary For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are generally characterized by higher volatility and deeper drawdowns than the broad...

Summary The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biotech CEFs (HQH) and (HQL) keep dropping to lower-and-lower valuations with HQH no...

Tekla Life Sciences ( NYSE: HQL ) declares $0.31/share quarterly dividend , -11.4% decrease from prior dividend of $0.35. Forward yield 8.34% Payable Nov. 30; for shareholders of record Nov. 25; ex-div Nov. 23. See HQL Dividend Scorecard, Yield Chart, &am...

Summary THW is still continuing with a steady monthly payout and generating close to double-digit yield, and it is relatively better protected from market risk. THW failed to grow during the past six months, as its major holdings failed to generate price growth. However, total ret...